Special Issue

Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines

Message from the Guest Editors

A novel strain of coronavirus, SARS-CoV-2, the causative agent of coronavirus disease (COVID-19) was first identified in late 2019 and triggered a pandemic which has been ongoing since March 2020. The development of effective therapeutics is an urgent global priority to stop the spread of COVID-19 infections and prevent further fatalities. As such, a number of platforms such as drugs, vaccines, monoclonal antibodies, pharmacological therapy, plasma therapy, immune boosters, and alternative medicines have been explored. In this Special Issue of *Biologics*, the focus will be on the development of vaccines, pharmacological therapy, alternative medicines, monoclonal antibodies, plasma therapy, preclinical studies, clinical trials, replication, viral life cycle, and pathogenesis of SARS-CoV-2, as well as areas of identification of novel drug targets and any form of treatment models against COVID-19 infection. In vitro, in vivo, in silico, preclinical, and clinical trials are all welcome. This Special Issue is for reviews or original research papers on biologics against the SARS-CoV-2 virus/COVID-19.

Guest Editors

Prof. Dr. Vasso Apostolopoulos

Institute for Health and Sport, Victoria University, Melbourne, VIC 3011, Australia

Dr. Majid Davidson

Institute of Health and Sports, Victoria University, Melbourne, VIC 3011, Australia

Deadline for manuscript submissions

closed (31 December 2021)



Biologics

an Open Access Journal by MDPI

CiteScore 7.2



mdpi.com/si/74880

Biologics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biologics@mdpi.com

mdpi.com/journal/ biologics





Biologics

an Open Access Journal by MDPI

CiteScore 7.2



About the Journal

Message from the Editor-in-Chief

Biologics (ISSN 2673-8449) is an international, multidisciplinary, peerreviewed, and scientific open access, open source journal that encourages authors to submit high-quality original research papers, reviews, and communications in all areas of biologics derived from both novel and established biotechnologies. We invite you to contribute original researches, review articles, essays or short reports for consideration and publication in the journal. Rapid turnaround time and full open access offer the opportunity to make research results immediately available to scientific communities and the general public.

Editor-in-Chief

Prof. Dr. Raffaele Capasso

Department of Agricultural Sciences, University of Naples Federico II, 80055 Portici, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, EBSCO, and other databases.

Journal Rank:

CiteScore - Q1 (Immunology and Microbiology (miscellaneous))

